Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392206 · ClinicalTrials.gov registry record · Phase 1
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
A Phase 1 study of End Stage Renal Disease, sponsored by Houssam Farres, M.D..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04392206 is a Phase 1 study of End Stage Renal Disease that is actively recruiting participants, run by Houssam Farres, M.D.. The registered enrollment target is 15 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04392206, a Phase 1 study of End Stage Renal Disease, is actively recruiting participants, sponsored by Houssam Farres, M.D..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.
Conditions Studied
Interventions
- DRUG Adipose Derived Mesenchymal Stem Cells
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-05-15 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04392206
The ClinicalTrials.gov registry entry for NCT04392206 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The listed sponsor is Houssam Farres, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Adipose Derived Mesenchymal Stem Cells is the first listed.
NCT04392206 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04392206 about?
NCT04392206 is a clinical study titled "AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses". Researchers are evaluating the safety of allogeneic Adipose Derived Mesenchymal Stem Cells (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its efficacy on improving access maturation and primary anastomotic patency.
What is the current status of trial NCT04392206?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-05-15. Estimated completion is 2027-06.
What conditions does trial NCT04392206 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT04392206?
The interventions under investigation include: Adipose Derived Mesenchymal Stem Cells (DRUG).
Who is sponsoring clinical trial NCT04392206?
This trial is sponsored by Houssam Farres, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04392206 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.